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Abstract: Pulmonary artery remodelling it is a major feature of pulmonary hypertension (PH). It is characterised 
by cellular and structural changes of the pulmonary arteries causing higher pulmonar vascular resistance and 
right ventricular failure. Abnormal deposition of smooth muscle-like (SM-like) cells in normally non-muscular, small 
diameter vessels and a deregulated control of endothelial cells are considered pathological features of PH. The 
origin of the SM-like cells and the mechanisms underlying the development and progression of this remodelling 
process are not understood. Endothelial cells within the intima may migrate from their organised layer of cells and 
transition to mesenchymal or SM-like phenotype in a process called endothelial-mesenchymal transition (EnMT). 
Traditionally, Waddington’s epigenetic landscape illustrates that fates of somatic cells are progressively determined 
to compulsorily follow a downhill differentiation pathway. EnMT induces the transformation of cells with stem cell 
traits, therefore contrasting Waddington’s theory and confirming that cell fate seems to be far more flexible than 
previously thought. The prospect of therapeutic inhibition of EnMT to delay or prevent PH may represent a promising 
new treatment modality. 
Keywords: Endothelial to mesenchymal transition, remodelling, endothelial cells, pulmonary hypertension, cellular 
reprogramming
Pulmonary hypertension
Pulmonary hypertension (PH) is a complex 
and progressive disease characterised by 
increased blood pressure in pulmonary arter-
ies. Hemodynamically, it is defined by a mean 
pulmonary artery pressure at rest exceeding 25
mmHg [1]. Pulmonary vessel remodelling, 
which consists of intimal, medial and adventi-
tial hypertrophy, leads to a reduction of the vas-
cular lumen [2]. This causes an increase in pul-
monary resistance, severe PH, right ventricular 
failure, and early death [3]. Currently, there is 
no cure for PH, but available treatments can 
lessen symptoms and improve quality of life. 
PH can occur due to genetic or sporadic causes, 
but the exact basis of PH remain unknown 
[4, 5]. 
Pulmonary arterial remodelling
Pulmonary artery remodelling it is a major fea-
ture of PH. It is characterised by cellular and 
structural changes affecting all three layers 
of the vessel wall of the pulmonary arteries [6, 
7]. Common pulmonary vascular remodelling 
changes in PH include increased intimal and/or 
medial stiffening and thickening, elevated ex- 
pression of smooth muscle α-actin, collagen 
synthesis/deposition, and inflammation [8]. 
Abnormal deposition of smooth muscle-like 
(SM-like) cells in normally non-muscular, small 
diameter vessels and a deregulated control of 
endothelial cells are considered important 
pathological features of PH [9]. Also, increased 
production of extracellular matrix proteins, with 
deposition of collagen and elastin contribute to 
lumen narrowing and PH [10]. It is this remodel-
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ling process inside the pulmonary vessels that 
is responsible for elevation of pulmonary vas-
cular resistance, progressive PH, right ventricu-
lar failure and finally death [11]. 
The origin of the SM-like cells and the mecha-
nisms underlying the development and pro-
gression of this remodelling process are not 
completely understood. It is been thought that 
muscularisation of the intimal layer of the ves-
sel wall is caused by proliferation of resident 
vascular smooth muscle cells of the medial 
layer which migrate to the intima [12, 13] 
(Figure 1A). Smooth muscle cells of the medial 
layer retain high cell plasticity and, under spe-
cific circumstances, can undergo phenotypic 
switch towards a synthetic or “de-differentiat-
ed” state. De-differentiated SMCs express high 
levels of extracellular matrix components and 
reduced expression of SMC contractile pro-
teins. In contrast to differentiated SMCs, de-
differentiated SMCs become highly prolifera-
tive and migratory [14, 15]. Recently, other 
possible sources of SM-like cells in the intimal 
layer of pulmonary vessels have been postu-
lated. Circulating progenitor cells have been 
shown to be recruited to sites of vascular injury 
and assume a SM-like phenotype [16-19] 
(Figure 1B). Resident progenitor cells present 
in the adventitia have also been postulated to 
be involved in vascular remodelling [20] (Figure 
1C). Additionally, resident endothelial cells 
within the intima may delaminate from their 
organised layer of cells in the vessel lining, 
transition to mesenchymal or SM-like pheno-
type in a process called endothelial-mesenchy-
mal transition (EnMT) and migrate to their 
underlying tissue [13, 21] (Figure 1D). In vitro, 
these altered cells have an indistinguishable 
morphology from de-differentiated SMCs and 
express abundant extracellular matrix proteins. 
In this review we will go over the evidences for 
EnMT of vascular endothelial cells and its 
potential implications in PH.
Endothelial-mesenchymal transition (EnMT)
Endothelial cells may contribute to vascular 
remodelling through EnMT. This is a process of 
endothelial cell “transformation” into mesen-
Figure 1. The origin of the SM-like cells in pulmonary arterial remodelling. Resident vascular smooth muscle cells 
(SMCs) from the medial layer retain high cell plasticity and, under specific circumstances, undergo phenotypic 
switch towards a synthetic or “de-differentiated” state (A). Differentiated SMCs become highly proliferative and 
migratory. Circulating progenitor cells could be recruited to sites of vascular injury and assume a SM-like phenotype 
(B). Resident progenitor cells in the adventitia may also serve as a source of SM-like cells and contribute to the 
pathophysiological changes in vascular structure (C). Additionally, Endothelial cells within the intima may migrate 
from their organised layer of cells and transition to mesenchymal or SM-like phenotype in a process called endothe-
lial-mesenchymal transition (EnMT) (D).
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chymal cells, by which endothelial cells lose 
their endothelial characteristics and gain a 
spindle shaped mesenchymal-like phenotype 
[22, 23]. EnMT is a central process during 
embryonic development [24-26]. In heart devel-
opment, endocardial cells with a clearly endo-
thelial phenotype are able to give rise to mes-
enchymal heart cushion cells through a process 
of EnMT [27-29]. Arciniegas et al, have also 
shown that EnMT is an important event in aor-
tic and pulmonary artery development [30] and 
in the development of the normal arterial inti-
ma [31]. Moreover, morphological studies in 
human embryos suggest that EnMT also occurs 
during the maturation of both arteries and 
veins [32]. 
Recently, some studies have shown that EnMT 
could also happen in adult life in a variety of 
pathologic settings, including PH [33, 34], ath-
erosclerosis [35] and wound healing [36]. In 
1997, Romero et al showed that capillary endo-
thelial cells could undergo mesenchymal tran-
sition in response to chronic inflammatory stim-
uli [37]. Additionally, a number of in vitro studies 
have demonstrated that endothelial cells from 
a variety of vascular beds retain the ability to 
transition into mesenchymal or SM-like cells 
under specific culture conditions [38, 42]. 
A loss of cell-to-cell contact seems to be a trig-
gering step in the development of EnMT [43]. 
Cell-cell adhesion glycoprotein, VE-cadherin, 
plays an important role in vascular biology by 
controlling the cohesion and organization of 
cell-cell junctions. The loss of expression of 
VE-cadherin, consistently preceded endothelial 
phenotype downregulation and SM-like trans-
formation [44]. 
Signalling during EnMT
There are several key signalling pathways con-
tributing to the remodelling process and to 
date, a number of studies have demonstrated 
the induction of EnMT in vitro. It has been sug-
gested that the TGF-β1 signalling pathway is 
involved in EnMT [45]. Both mouse and human 
endothelial cells cultured in the presence of 
TGF-β1 have shown SM-like cell morphology 
and an up-regulation of α-SM actin [46-48]. 
Recently, studies have shown that both TGF-β1 
and Wnt-signalling pathways could synergize in 
the EnMT process [49, 50]. Moreover, in addi-
tion to TGF-β1 and Wnt-signalling pathways, the 
Notch pathway has also been shown to be 
involved in both vascular development and inti-
mal lesion formation processes [51-53]. 
Although it is known that all these signalling 
pathways contribute to EnMT, it is not clear 
whether Notch, Wnt, TGF-β1, or the combina-
tion of all pathways, provide the initiation signal 
for EnMT in vivo [54]. Furthermore, it is likely 
that other signalling pathways such as VEGF, 
NFAT and BMP, which interact with TGF-β1 and 
Notch signalling, also mediate EnMT [55].
Despite these signalling studies, the transcrip-
tional networks which mediate EnMT remain 
largely unidentified. Recently, the role of the 
Snail family of transcriptional repressors has 
been highlighted in control of different tran-
scriptional programs of mesenchymal stem cell 
differentiation [56]. Snail proteins including 
Slug are involved in a broad spectrum of bio-
logical functions including epithelial to mesen-
chymal transition (EMT), cell differentiation, 
cell motility, cell-cycle regulation and apopto-
sis. In the context of EnMT, Snail and Slug play 
a critical role in disrupting cell-cell junctions 
and down-regulating VE-cadherin gene expres-
sion [57-59]. 
EMT/EnMT
EnMT is related to the more generally recog-
nized mechanism of somatic cell plasticity; 
epithelial-to-mesenchymal transition (EMT) 
[60]. EMT involves a phenotypic cellular switch, 
in this case, from an epithelial to mesenchymal 
phenotype [61]. EnMT, EMT and its reverse 
pathway, mesenchymal to epithelial transition 
(MET) are key biological processes that occur 
naturally during embryonic life [62, 63]. Cellular 
switching from an epithelial to mesenchymal 
phenotype (EMT), and conversely from a mes-
enchymal to epithelial phenotype (MET) are 
important biologic programs fundamental to 
the generation of several complex body pat-
terns throughout evolution [64, 65]. EMT plays 
a central role in germ layer specification (endo-
derm, ectoderm and mesoderm) and a range of 
different recurrent EMT/MET cycles occur 
before final organ formation [66]. In lungs for 
example, EMT is a natural process that exists to 
allow airway branching during fetal develop-
ment. During cardiac development, EMT/MET 
is crucial in valve formation and heart septation 
[67]. In other organs, such as the kidney, suc-
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cessive phases of EMT/MET are necessary to 
ultimately give rise to nephrons or nephric 
ducts [68]. Moreover in the adult, EMT contrib-
utes to pathology of tissue fibrosis, tumour pro-
gression, and tumour metastasis, which results 
when cells delaminate from the primary tumour, 
allows them to migrate [69, 70].
Cellular reprogramming 
Traditionally, Waddington’s epigenetic land-
scape illustrates that fates of somatic cells are 
progressively determined to compulsorily follow 
a downhill differentiation pathway [71] (Figure 
2A). As such any reversal of cell differentiation 
Figure 2. Cellular differentiation and reprogramming patterns. Waddington’s epigenetic landscape. Somatic cells 
take on a specific fate by compulsorily progressing from the pluripotent state to a terminal differentiated state (A). 
Transdifferentiation. A mature cell switches its phenotype and function to that of another mature differentiated cell 
type without undergoing an intermediate pluripotent state or becoming a progenitor cell (B). Dedifferentiation of 
reprogramming to pluripotency. Differentiated cells return to an immature state and regain pluripotency (C). EMT/
EnMT; partial dedifferentiation. Cells change their specific fate, dedifferentiate and acquire a more immature, pro-
liferative phenotype from another somatic lineage without converting to a pluripotent cell (D).
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status would require external intervention in 
nuclear function such as nuclear transfer [72, 
73] or the introduction of several transcription 
factors [74]. The plasticity of somatic cell fate is 
a complex concept that has evolved through 
decades of research. It is currently known that 
some somatic cells seem to possess a greater 
plasticity when exposed to certain stimuli. 
Smith et al, showed in 1998 that Oct4 tran-
scription factor is required for maintaining 
mouse embryonic stem cell pluripotency [75], 
and in 2006 Takahashi and Yamanaka et al, 
were able to reprogram mouse fibroblasts to 
induced pluripotent stem cells (iPS) using 4 
transcription factors (Sox2, Klf4, Oct4 and 
c-Myc) [76]. EMT and EnMT are examples of 
remarkable somatic cell plasticity occurring 
naturally though organogenesis. There is cur-
rent evidence that cells undergoing EMT/EnMT 
acquire stem cell properties [77, 78] and it has 
recently been postulated that MET is a key cel-
lular mechanism required for transforming 
somatic cells toward the generation of induced 
pluripotent stem cells [79]. Li et al, showed that 
while Sox2/Oct4 upregulation suppresses the 
EMT mediator Snail, c-Myc downregulates TGF-
β1 and TGF-β receptor 2, whilst, Klf4 induces 
the expression of epithelial genes including 
E-cadherin [80]. These recent findings are 
important and raise many questions. They 
oppose Waddington’s epigenetic view in which 
a fully differentiated cell had completed a 
downhill journey into a valley from which it 
could not then escape. Cell fate seems now to 
be far more flexible than previously thought 
[81].
Transdifferentiation refers to a process where 
one mature cell switches its phenotype and 
function to that of another mature differentiat-
ed cell type without undergoing an intermedi-
ate pluripotent state or becoming a progenitor 
cell [82] (Figure 2B). Davis et al, showed in 
1987, that mouse embryonic fibroblasts could 
transdifferentiate directly into mature myo-
blasts [83]. EMT/EnMT induces the generation 
of cells with stem cell traits, thus it does not 
fulfil Takahashi’s definition of transdifferentia-
tion. Dedifferentiation is a process which 
induces cell rejuvenation. It refers to a process 
where cells travel back up their differentiation 
path, to become more immature and finally 
convert into a pluripotent cell [84] (Figure 2C). 
EMT/EnMT could be considered an initial stage 
of cellular dedifferentiation or reprogramming 
processes where cells dedifferentiate and 
acquire a more immature, proliferative pheno-
type but do not convert to a pluripotent cell. 
Cellular reprogramming and change of cell fate 
decisions through EMT/EnMT provides new 
ways to traverse across Waddington’s epigene-
tic landscape (Figure 2D). As EMT/EnMT are 
essential and occurs frequently during embry-
onic development one could postulate that cel-
lular reprogramming occurs spontaneously in 
the embryo and in certain adult pathological 
conditions. 
Reversibility of EMT/EnMT. Future perspec-
tives
During embryogenesis, EMT and its reverse 
process, MET, occur spontaneously during 
organ morphogenesis [85]. However, less is 
known about the reversibility of EnMT [86]. It 
has been suggested that endothelial cells 
transformed to a more SM-like cell phenotype 
could be restored by administration of FGF 
[87]. Recently our group have shown that in 
vitro, following withdrawal of TNF-α, SM-like 
cells acquired a normal phenotype (manuscript 
submitted). However, more studies are neces-
sary to determine the reversibility of this EnMT 
process in vitro and in vivo. 
It is accepted that EMT/EnMT occurs not only 
during embryonic development but also in the 
pathogenesis of various cardiovascular diseas-
es such as heart failure and PH. The prospect 
of therapeutic manipulation of EnMT/EMT in 
the treatment of these conditions is particularly 
attractive [88, 89]. In particular, therapies 
directed at inhibiting EnMT to delay or prevent 
PH, may represent a promising new treatment 
modality. Nevertheless, additional studies are 
needed to identify the precise molecular mech-
anism of EnMT in disease, to provide novel 
insights into the mechanisms of such diseases 
and to determine which signalling components 
might be viable therapeutic targets.
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